Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 19/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.71 |
| ▸ | PDE4A | P27815 | 14/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050370 | 0.90 | PDE4B (0.58) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7359780 | 0.88 | PDE4B (0.76) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL720381 | 0.88 | PDE4D (0.73) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL24530806 | 0.87 | PDE4D (0.71) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30513591 | 0.86 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL28607507 | 0.86 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL23509515 | 0.85 | PDE4B (0.82) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29033058 | 0.85 | PDE4B (0.98) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL28150332 | 0.85 | PDE4B (0.98) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7352724 | 0.84 | PDE4B (0.73) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321726-B2 | Process for preparing roflumilast | INTERQUIM, S.A. (ES) | 2016-04-26 | — | — | US | disclosed |
| US-20150246884-A1 | PROCESS FOR PREPARING ROFLUMILAST | INTERQUIM, S.A. (ES) | 2015-09-03 | — | — | US | disclosed |
| WO-2014115098-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION | KANDULA MAHESH (IN) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246884-A1 | PROCESS FOR PREPARING ROFLUMILAST | ESD, DNTT, HPD | PDE4D 969/4885PDE4B 1052/4885PDE4A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.